The increasing use of high-flux membranes for hemodialysis (HD) has raised concerns that these membranes may confer a higher risk of exposure to cytokine-inducing, bacterial substances (CIS) in the dialysate. Several studies, however, reported higher transfer of CIS through low-flux cellulosic than high-flux synthetic membranes. This surprising paradox was explained by adsorption of CIS to certain high-flux membranes. In order to investigate flux and membrane type independently, we studied two synthetic Polyflux (PF) membranes of the same type but with different flux properties and compared them to a cellulosic membrane (Cuprophan). Three different approaches were employed: (1) cytokine induction in whole blood during in vitro HD contaminated with bacterial filtrates, (2) removal of recombinant C5a, and (3) transfer of purified lipopolysaccharide (LPS). After 90 min recirculation of whole blood, the appearance of IL-6-inducing substances on the blood side was lowest with high-flux PF (1.1 +/- 0.2 ng/ml), slightly higher with low-flux PF (1.9 +/- 0.7 ng/ml) and highest with Cuprophan (4.1 +/- 1 ng/ml). Recombinant C5a added to plasma on the blood side was markedly removed by high-flux PF (by 83%), to a lesser degree and only in the presence of ultrafiltration with low-flux PF (by 54%) and not significantly with Cuprophan (by 11%). Significant transfer of purified LPS from the dialysate onto the blood side was only observed with the cellulosic membrane. We conclude that in contrast to cellulosic membranes, certain synthetic membranes do not permit transfer of LPS. Cytokine induction on the blood side is further reduced by the use of high-flux membranes due to removal of activated complement factors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000090520 | DOI Listing |
J Thorac Dis
December 2024
Department of Thoracic Surgery, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
Background: Chylothorax following esophagectomy is a frustrating complication with considerable morbidity. In addition, recognizing the morphological patterns of the thoracic duct (TD) holds great significance. This study was aimed at explore the safety and efficacy of three-dimensional (3D) thoracoscope in comparison with indocyanine green (ICG) fluorescence to identify TD during minimally invasive esophagectomy (MIE) for esophageal cancer.
View Article and Find Full Text PDFCureus
December 2024
Oncology, Oxford University Hospitals National Health Services (NHS) Foundation Trust, Oxford, GBR.
Prostate cancer is one of the most frequently diagnosed cancers and poses a significant health burden. New androgen-targeted therapies are now standard treatments for various stages of prostate cancer, including hormone-sensitive, metastatic, and non-metastatic castration-resistant types. These therapies are generally well tolerated and often have fewer side effects compared to traditional chemotherapy.
View Article and Find Full Text PDFIntroduction: GLP-1 medications are widely used for weight loss in patients with and without type 2 diabetes. However, limited research exists on their effects in non-diabetic patients, particularly concerning mitochondrial function. This case report investigates the potential of altered mitochondrial dysfunction as a cause of side effects of GLP-1 medications in patients without type 2 diabetes.
View Article and Find Full Text PDFTher Adv Respir Dis
January 2025
Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Beitou District, Taipei City 11217, Taiwan.
Background: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan.
Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral corticosteroids (OCS) or emergency department (ED) visits and/or hospitalizations) in the 12 months pre- and post-mepolizumab treatment. Secondary objectives assessed changes in the number of CSEs requiring ED visits/hospitalizations and daily maintenance OCS (mOCS) dosage 12 months pre- and post-mepolizumab treatment.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Chi Mei Medical Center, Tainan, Liouying, Taiwan.
Introduction: Venetoclax, an oral B-cell lymphoma-2 (BCL-2) inhibitor, shows promise in cancer treatment but has an unclear safety profile. This meta-analysis evaluates the safety of venetoclax, focusing on adverse events.
Methods: Data from PubMed, Embase, Cochrane databases, and ClinicalTrials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!